Supernus Pharmaceuticals Inc (FRA:S49)
€ 34.6 0.6 (1.76%) Market Cap: 1.97 Bil Enterprise Value: 1.62 Bil PE Ratio: 34.78 PB Ratio: 2.04 GF Score: 80/100

Supernus Pharmaceuticals Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 02:10PM GMT
Release Date Price: €23.6 (+1.72%)
Unidentified Analyst

Good morning, good afternoon and good evening depending on where you are. My name is [Sreenivasan], and I'm a member of the JPMorgan Investment Banking team. It is my pleasure to introduce to you Jack Khattar, CEO of Supernus.

Jack, I'll turn it over to you.

Jack A. Khattar
Supernus Pharmaceuticals, Inc. - Founder, President, CEO, Secretary & Director

Thank you, and thanks for having us today. Good morning, everyone, and thanks for joining us. Before I start, I would like to start on Slide 2, just to remind everyone that I will be making forward-looking statements through the presentation as well as the Q&A session, so please refer to our SEC filings for all the risk factors associated with our business.

Turning to Slide 3. It shows you the execution in CNS and the experience in CNS that Supernus has had over so many years, 20-plus years of CNS expertise. Developing actually 4 products in ADHD, and that is very relevant to us today as we speak a little bit more in details about SPN-812, which is our lead pipeline asset

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot